ERBB2 and breast cancer: Importantly, the method demonstrates the ability to distinguish between different types of breast cancer exosomes, including HER2-positive and HER2-negative subtypes, and exhibits compatibility with complex sample matrices, offering promising prospects for the screening and prognosis of breast cancer by exosome analysis.